FDAsafety guidance77% confidence
FDA AP — CHILDREN'S ALLEGRA HIVES (SUPPL)
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (ild) as Merck; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA021909. Sponsor: CHATTEM SANOFI. Submission status: AP. Submission type: SUPPL. Review priority: STANDARD. Active ingredients: FEXOFENADINE HYDROCHLORIDE.
Supporting Context
- Therapeutic area
- Infectious Disease · Pneumococcal Vaccine
- Sub-indication
- Ild
Related signal: FDA Approves CAPVAXIVE for At-Risk Children and Adolescents